← Back to Screener
electroCore, Inc. Common Stock (ECOR)
Price$8.72
Value ScoreC
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)64.75%
Price vs S&P 500 (4W)36.05%
VGM Score67.92
Market Capitalization$72.34M
All Metrics
Book Value / Share (Quarterly)$0.15
P/TBV (Annual)1.95x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)55.07%
Cash Flow / Share (Quarterly)$-0.85
Price vs S&P 500 (YTD)86.27%
Gross Margin (TTM)87.68%
Net Profit Margin (TTM)-44.08%
EPS (TTM)$-1.78
10-Day Avg Trading Volume0.26M
EPS Excl Extra (TTM)$-1.78
Revenue Growth (5Y)55.71%
EPS (Annual)$-1.65
ROI (Annual)-157.56%
Gross Margin (Annual)87.22%
Net Profit Margin (5Y Avg)-156.44%
Cash / Share (Quarterly)$1.09
Revenue Growth QoQ (YoY)42.64%
ROA (Last FY)-74.82%
Revenue Growth TTM (YoY)31.90%
EBITD / Share (TTM)$-1.65
ROE (5Y Avg)-137.89%
Operating Margin (TTM)-41.97%
Cash Flow / Share (Annual)$-1.03
P/B Ratio64.99x
P/B Ratio (Quarterly)35.20x
Net Income / Employee (Annual)$-168,300
EV / Revenue (TTM)2.13x
Net Interest Coverage (TTM)-46.82x
ROA (TTM)-87.75%
EPS Incl Extra (Annual)$-1.65
Current Ratio (Annual)1.38x
Quick Ratio (Quarterly)0.79x
3-Month Avg Trading Volume0.08M
52-Week Price Return62.69%
Revenue / Employee (TTM)$420,400
Tangible BV / Share (Quarterly)$1.84
P/S Ratio (Annual)2.26x
Asset Turnover (Annual)1.72x
52-Week High$10.37
Operating Margin (5Y Avg)-161.47%
EPS Excl Extra (Annual)$-1.65
Tangible BV CAGR (5Y)-11.91%
26-Week Price Return72.67%
Quick Ratio (Annual)1.11x
13-Week Price Return15.96%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.02x
Enterprise Value$74.17M
Revenue / Share Growth (5Y)22.91%
Asset Turnover (TTM)1.99x
Book Value / Share Growth (5Y)-37.81%
Revenue / Employee (Annual)$385,900
Inventory Turnover (Annual)2.48x
Pretax Margin (Annual)-43.59%
Cash / Share (Annual)$1.45
3-Month Return Std Dev103.16%
Gross Margin (5Y Avg)82.13%
Net Income / Employee (TTM)$-185,300
ROE (Last FY)-157.56%
Net Interest Coverage (Annual)-17.40x
EPS Basic Excl Extra (Annual)$-1.65
Receivables Turnover (TTM)29.94x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.78
Receivables Turnover (Annual)26.76x
ROI (TTM)-235.81%
P/S Ratio (TTM)2.07x
Pretax Margin (5Y Avg)-160.87%
Revenue / Share (Annual)$3.78
Tangible BV / Share (Annual)$3.60
Price vs S&P 500 (52W)38.32%
Year-to-Date Return94.43%
5-Day Price Return-15.75%
EPS Normalized (Annual)$-1.65
ROA (5Y Avg)-75.91%
Net Profit Margin (Annual)-43.60%
Month-to-Date Return-10.66%
Cash Flow / Share (TTM)$-3.91
EBITD / Share (Annual)$-1.49
Operating Margin (Annual)-41.06%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-136.59%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.78
P/TBV (Quarterly)3.02x
P/B Ratio (Annual)14.08x
Inventory Turnover (TTM)2.32x
Pretax Margin (TTM)-44.85%
Book Value / Share (Annual)$1.13
Price vs S&P 500 (13W)7.70%
Beta0.91x
Revenue / Share (TTM)$3.90
ROE (TTM)-235.81%
52-Week Low$4.16
vGradeC
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.37est. -0.62
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.18
4.18
4.18
4.18
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ECORelectroCore, Inc. Common Stock | C | A | B | $8.72 |
| MDTMedtronic plc | B | C | C | $81.67 |
| MASIMasimo Corporation | D | D | B | $178.82 |
| LIVNLivaNova PLC Ordinary Shares | C | C | B | $72.36 |
| ITGRInteger Holdings Corporation | B | C | C | $91.98 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | $69.43 |
| AXGNAxogen, Inc. Common Stock | F | B | A | $42.80 |
| BLFSBioLife Solutions Inc. | F | B | B | $26.65 |
| CNMDCONMED Corporation | A | C | D | $35.16 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | $13.54 |
| CBLLCeriBell, Inc. Common Stock | D | A | B | $18.25 |
About
electroCore Inc develops and commercializes gammaCore, an FDA-cleared non-invasive vagus nerve stimulation device for treating neurological disorders. The platform is approved for the acute and preventive treatment of migraine and cluster headaches in adults, as well as additional headache indications. electroCore is a commercial-stage bioelectronic medicine company leveraging neuromodulation technology in the neurology market.